Supratentorial primitive neuroectodermal tumours of the brain: Multidirectional differentiation does not influence prognosis. A clinicopathological report of 18 patients

Histopathology

Volumn 46, Issue 4, 2005, Pages 403-412

  Visee S ^a   Soltner, C ^a   Rialland, X ^a   Machet, M C ^b   Loussouarn, D ^c   Milinkevitch, S ^d   Pasco Papon, A ^a   Mercier, P ^a   Rousselet, Marie Christine ^a  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

Brain neoplasms; Immunohistochemistry; Prognosis; Supratentorial primitive neuroectodermal tumours

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANTIBODY; CALDESMON; CHROMOGRANIN A; CYTOKERATIN; DESMIN; EPITHELIAL MEMBRANE ANTIGEN; FORMALDEHYDE; GLIAL FIBRILLARY ACIDIC PROTEIN; H CALDESMON; MYOGENIN; NEUROFILAMENT PROTEIN; NEURON SPECIFIC ENOLASE; PARAFFIN; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CANCER SURVIVAL; CELL DIFFERENTIATION; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID CYTOLOGY; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MALE; NEUROECTODERM TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TUMOR CLASSIFICATION; TUMOR RECURRENCE;

ADOLESCENT; ADULT; ANTIGENS, CD; BRAIN NEOPLASMS; CA-15-3 ANTIGEN; CELL ADHESION MOLECULES; CELL DIFFERENTIATION; CHILD; CHILD, PRESCHOOL; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; MALE; MIDDLE AGED; NEUROECTODERMAL TUMORS, PRIMITIVE; NEUROFILAMENT PROTEINS; PHOSPHOPYRUVATE HYDRATASE; PROGNOSIS; SURVIVAL ANALYSIS; SYNAPTOPHYSIN;

EID: 17144370976     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2005.02101.x     Document Type: Article

References (30)

1. Gaffney CC, Sloane JP, Bradley NJ, Bloom HJG. Primitive neuroectodermal tumours of the cerebrum. Pathology and treatment. J. Neuro-Oncol. 1985; 3; 23-33.
2. Kim DG, Lee DY, Pack SH, Chi JG, Choe G, Jung HW. Supratentorial primitive neuroectodermal tumors in adults. J. Neuro-Oncol. 2002; 60; 43-52.
3. Kleihues P, Cavenee WK, eds. World Health Organisation classification of tumours: pathology and genetics of tumours of the nervous system. Lyon: IARC Press, 2000.
4. Rorke LB. The cerebellar medulloblastoma and its relationship to primitive neuroectodermal tumors. J. Neuropathol. Exp. Neurol. 1983; 42; 1-15.
5. Rubinstein LJ. Justification for a cytogenetic scheme of embryonal central neuroepithelial tumors. In Fields WS ed. Primary brain tumors: a review of histological classification. New York: Springer, 1989; 16-27.
6. Janss AJ, Yachnis AT, Silber JH et al. Glial differentiation predicts poor clinical outcome in primitive neuroectodermal brain tumors. Ann. Neurol. 1996; 39; 481-489.
7. Paulino AC, Melian E. Medulloblastoma and supratentorial primitive neuroectodermal tumors. An institutional experience. Cancer 1999; 86; 142-148.
8. McNeil DE, Coté TR, Clegg L, Rorke LB. Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Med. Pediatr. Oncol. 2002; 39; 190-194.
9. Cohen BH, Zelter PM, Boyett JM et al. Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy: a children cancer group randomized trial. J. Clin. Oncol. 1995; 13; 1687-1696.
10. Dirks PB, Harris L, Hoffman HJ, Humphreys RP, Drake JM, Rutka JT. Supratentorial primitive neuroectodermal tumors in children. J. Neuro-Oncol. 1996; 29; 75-84.
11. Mikaeloff Y, Raquin MA, Lellouch-Tubiana A et al. Primitive cerebral neuroectodermal tumors excluding medulloblastoma: a retrospective study of 30 cases. Pediatr. Neurosurg. 1998; 29; 170-117.
12. Reddy AT, Janss AJ, Phillips PC, Wiess HL, Packer RJ. Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. Cancer 2000; 88; 2189-2193.
13. Marec-Berard P, Jouvet A, Thiesse P, Kalifa C, Doz F, Frappaz D. Supratentorial embryonal tumors in children under 5 years of age: an SFOP study of treatment with postoperative chemotherapy alone. Med. Pedriatr. Oncol. 2002; 38; 83-90.
14. Timmermann B, Kortmann RD, Kühl J et al. Role of radiotherapy in the treatment of supratentorial primitive neuroectodermal tumors in childhood: results of the prospective German brain tumor trials HIT 88/89 and 91. J. Clin. Oncol. 2002; 20; 842-849.
15. Albright AL, Wisoff JH, Zelter P et al. Prognostic factors in children with supratentorial (nonpineal) primitive neuroectodermal tumors. A neurosurgical perspective from the Children's Cancer Group. Pediatr. Neurosurg. 1995; 22; 1-7.
16. Pomeroy SL, Tamayo P, Gaasenbeek M et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002; 415; 436-442.
17. Ganti SR, Silver AJ, Dieffenbach P, Hilal SK, Mawad ME, Sane P. Computed tomography of primitive neuroectodermal tumors. Am. J. Neuroradiol. 1983; 4; 19-21.
18. Robles HA, Smirniopoulos JG, Figueroa R. Understanding the radiology of intracranial primitive neuroectodermal tumors from a pathological perspective: a review. Semin. Ultrasound CT MR 1992; 13; 170-181.
19. Grant JW, Steart PV, Gallagher PJ. Primitive neuroectodermal tumors of the cerebrum. A histological and immunohistochemical study of 10 cases. Clin. Neuropathol. 1988; 7; 228-233.
20. Dehner LP, Abenoza P, Sibley RK. Primary cerebral neuroectodermal tumors: neuroblastoma, differentiated neuroblastoma, and composite neuroectodermal tumor. Ultrastruct. Pathol. 1988; 12; 479-494.
21. Gould VE, Jansson DS, Molenaar WM et al. Primitive neuroectodermal tumors of the central nervous system. Patterns of expression of neuroendocrine markers, and all classes of intermediate filament proteins. Lab. Invest. 1990; 62; 498-509.
22. Gould VE, Rorke LC, Jansson DS et al Primitive neuroectodermal tumors of the central nervous system express neuroendocrine markers, and may express all classes of intermediate filament. Hum. Pathol 1990; 21; 245-252.
23. Molenaar WM, Jansson DS, Gould VE et al. Molecular markers of primitive neuroectodermal tumors and other pediatric central nervous system tumors. Monoclonal antibodies to neuronal and glial antigens distinguish subsets of primitive neuroectodermal tumors. Lab. Invest. 1989; 61; 635-643.
24. Zeltzer PM, Bodey B, Marlin A, Kemshead J. Immunophenotype profile of childhood medulloblastomas and supratentorial primitive neuroectodermal tumors using 16 monoclonal antibodies. Cancer 1990; 66; 273-283.
25. Wikstrand CJ, Fung KM, Trojanowski JQ, McLendon RE, Bigner DD. Antibodies and molecular immunology. In Bigner DD, McLendon RE, Bruner JM eds. Russel and Rubinstein's pathology of tumors of the nervous system. London: Arnold, 1998.
26. Abenoza P, Wick MR. Primitive cerebral neuroectodermal tumor with rhabdomyoblastic differentiation. Ultrastruct. Pathol. 1986; 10; 347-354.
27. Biegel JA, Zhou JY, Rorke LB, Stenstrom C, Wainwright LM, Fogelgren B. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 1999; 59; 74-79.
28. Judkins AR, Mauger J, Rorke LB, Biegel JA. Immunohistochemical analysis of HSNF5/INI1 in pediatric CNS neoplasms. Am. J. Surg. Pathol. 2004; 28; 644-650.
29. Gyure KA, Prayson RA, Estes ML. Extracerebellar primitive neuroectodermal tumors: a clinicopathologic study with bcl2 and CD99 immunohistochemistry. Ann. Diagn. Pathol. 1999; 3; 276-280.
30. Choi YL, Chi JG, Suh YL. CD99 immunoreactivity in ependymoma. Appl. Immunohistochem. Mol. Morph. 2001; 9; 125-129.